These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30928161)

  • 1. Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al's Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:e53.
    Leibowitz-Amit R
    Eur Urol; 2019 Jul; 76(1):e19. PubMed ID: 30928161
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al.'s Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:e51-2.
    On Behalf Of Ema
    Eur Urol; 2019 Mar; 75(3):e53. PubMed ID: 30658854
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Kenneth A. Iczkowski's Letter to the Editor re: Re: Rodolfo Montironi, Silvia Gasparrini, Roberta Mazzucchelli, et al's Letter to the Editor re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. Eur Urol 2016;70:738-9: Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and Seminal Vesicles as Observed in Virtual Whole-mount Histologic Slides. Eur Urol 2017;71:e73-5.
    Montironi R; Lopez-Beltran A; Cheng L; Gasparrini S; Montironi MA; Massari F; Scarpelli M; Montorsi F
    Eur Urol; 2017 Aug; 72(2):e37-e38. PubMed ID: 28292549
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Rodolfo Montironi, Silvia Gasparrini, Roberta Mazzucchelli, et al's Letter to the Editor re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. Eur Urol 2016;70:738-9: Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and Seminal Vesicles as Observed in Virtual Whole-mount Histologic Slides. Eur Urol 2017;71:e73-5.
    Iczkowski KA
    Eur Urol; 2017 Aug; 72(2):e36. PubMed ID: 28284740
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Piet R. Dirix, Carole Mercier, and Luc Y. Dirix's Letter to the Editor re: Fabian Lohaus, Klaus Zöphel, Steffen Löck, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol 2019;75:548-51.
    Hölscher T; Lohaus F; Wirth M; Troost EGC
    Eur Urol; 2019 Oct; 76(4):e103-e104. PubMed ID: 31256943
    [No Abstract]   [Full Text] [Related]  

  • 6. Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives.
    van der Doelen MJ; Mehra N; Hermsen R; Janssen MJR; Gerritsen WR; van Oort IM
    Clin Genitourin Cancer; 2019 Apr; 17(2):79-87. PubMed ID: 30558834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reply to Alessia Cimadamore, Marina Scarpelli, Liang Cheng, et al's Letter to the Editor, re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019, 76:871.
    Sighinolfi MC; Rocco B
    Eur Urol; 2020 May; 77(5):e128-e129. PubMed ID: 32067794
    [No Abstract]   [Full Text] [Related]  

  • 8. The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer.
    O'Sullivan JM; Heinrich D; James ND; Nilsson S; Ost P; Parker CC; Tombal B
    Eur Urol; 2019 Mar; 75(3):e51-e52. PubMed ID: 30454914
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to Salma Kaochar, Nicholas Mitsiades' Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652-6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer.
    Swami U; Antonarakis ES; Agarwal N
    Eur Urol; 2021 Mar; 79(3):e94-e95. PubMed ID: 33419681
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.
    McHenry MB; Drake CG; Fizazi K
    Eur Urol; 2021 Jan; 79(1):e12-e13. PubMed ID: 33121826
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to Robert J. van Soest and Ronald de Wit's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
    de Bono J
    Eur Urol; 2017 Jan; 71(1):e11. PubMed ID: 27751730
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Tuomas Mirtti and Tero Aittokallio's Letter to the Editor re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40. Clinical Utility of Trial-estimated Prognostic Models.
    Seyednasrollah F; Mahmoudian M; Rautakorpi L; Hirvonen O; Laitinen T; Jyrkkiö S; Elo LL
    Eur Urol; 2017 Sep; 72(3):e70-e71. PubMed ID: 28499619
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
    Loehr A; Chowdhury S; Abida W
    Eur Urol; 2023 Mar; 83(3):e78. PubMed ID: 36623951
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Ruobing Lei, Yuehuan Li, and Yaolong Chen's Letter to the Editor re: Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. Eur Urol 2022;81:503-14. Improving the Methodological Quality of Prostate Cancer Core Outcome Sets in Future Updates.
    Beyer K; MacLennan S; Van Hemelrijck M
    Eur Urol; 2022 Sep; 82(3):e68-e69. PubMed ID: 35688663
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
    Rescigno P; de Bono JS
    Eur Urol; 2016 Dec; 70(6):e170-e171. PubMed ID: 27240941
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Nicholas G. Zaorsky, Daniel E. Spratt, and Pierre Blanchard's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319-28.
    Moschini M; Zaffuto E; Mattei A; Karakiewicz PI; Shariat SF
    Eur Urol; 2019 Apr; 75(4):e98-e99. PubMed ID: 30503180
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Bernard Tombal's letter to the editor re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722-30.
    Sciarra A
    Eur Urol; 2014 Apr; 65(4):e57. PubMed ID: 24388442
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Giandomenico Roviello, Daniele Generali, and Roberto Petrioli's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
    de Bono JS
    Eur Urol; 2017 Feb; 71(2):e56. PubMed ID: 27544577
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to Kevin Lu's letter to the editor re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2015;67:441-7.
    Azad AA; Chi KN
    Eur Urol; 2015 Sep; 68(3):e57-8. PubMed ID: 25864159
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.02.013.
    Mehra N; Dolling D; de Bono J
    Eur Urol; 2018 Sep; 74(3):e69-e70. PubMed ID: 29866468
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.